Similares a Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes | ATS 2026

20 vecinos (text_768) · 122 views · HCPLive · Estados Unidos


★	Tezepelumab Reduced Severe Asthma Exacerbations Across Phenotypes \| ATS 2026	HCPLive @hcplivenews	122	Estados Unidos
4	Mepolizumab Add-On Reduces COPD Exacerbations in Triple-Therapy Patients \| ATS 2026	HCPLive @hcplivenews	1.2K	Estados Unidos	88
19	Diabetes Dialogue: FDA Approves Afrezza Inhaled Insulin for Pediatric Patients	HCPLive @hcplivenews	683	Estados Unidos	84
14	La Universitat se suma al Dia Europeu de Dèficit d'Alfa-1	Universitat de València @universitatvalencia	481	España	85
17	Inhaled Treprostinil for IPF: TETON-1 Phase 3 Results With Steven Nathan, MD \| ATS 2026	HCPLive @hcplivenews	301	Estados Unidos	84
15	The Truth About Omalizumab Safety and #Anaphylaxis Risk	HCPLive @hcplivenews	209	Estados Unidos	85
8	Mixed AERIFY Data May Delay Itepekimab Approval Pathway in COPD, With Klaus F. Rabe, MD, PhD	HCPLive @hcplivenews	198	Estados Unidos	87
5	Mepolizumab Reduced COPD Hospitalizations in Eosinophilic Disease \| ATS 2026 With Gerard Criner, MD	HCPLive @hcplivenews	113	Estados Unidos	88
7	AERIFY: Phase 3 Data Reveal Challenges, Potential of Itepekimab in COPD	HCPLive @hcplivenews	105	Estados Unidos	88
3	SUNRISE: Tezepelumab Shows Meaningful OCS Reduction in Severe Asthma	HCPLive @hcplivenews	78	Estados Unidos	90
18	How to Sequence Omalizumab, Dupilumab, and Remibrutinib in CSU	HCPLive @hcplivenews	74	Estados Unidos	84
6	Dupilumab Doubled Asthma Remission Odds in Type 2 Asthma:	HCPLive @hcplivenews	71	Estados Unidos	88
2	ATS 2026 Asthma Updates: Tezepelumab, Dupilumab, OCS Reduction & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	70	Estados Unidos	90
20	Robert Wood, MD, on Age, Dosing in Multifood Allergy OIT	HCPLive @hcplivenews	70	Estados Unidos	84
1	Tezepelumab Cuts Severe Asthma Exacerbations 70% in Real-World Patients \| ATS 2026	HCPLive @hcplivenews	68	Estados Unidos	97
12	Omalizumab vs Oral Immunotherapy for Multifood Allergy	HCPLive @hcplivenews	65	Estados Unidos	85
10	Can CSU Patients Achieve True Remission? BTK Inhibitors, Biomarker Barriers, & More \| EAC 2026	HCPLive @hcplivenews	58	Estados Unidos	86
11	ATS 2026 Pulmonology: AD109, Ralinepag, ALIS, Itepekimab & More \| HCPLive Expert Interviews	HCPLive @hcplivenews	55	Estados Unidos	86
16	SGLT2 Inhibitors May Reduce COPD Readmissions I ATS 2026	HCPLive @hcplivenews	48	Estados Unidos	84
9	Biologic Selection in Severe Asthma: Biomarkers, Comorbidities & Switching Strategies	HCPLive @hcplivenews	36	Estados Unidos	86
13	Pegtarazimod Cuts Oxygen Need in Hospitalized COPD Patients \| ATS 2026 \| Gerald Criner, MD	HCPLive @hcplivenews	29	Estados Unidos	85